Skip to main content
Clinical Trials/NCT02872220
NCT02872220
Completed
Not Applicable

A Randomized Study to Assess the Potential for Photoallergy of SPF 50 Y65 110, SPF 50 Y51 002 and SPF 15 V27 104 in Human Subjects

Bayer0 sites56 target enrollmentMarch 23, 2015

Overview

Phase
Not Applicable
Intervention
SPF 50 Y65 110 (BAY987519)
Conditions
Photoallergy
Sponsor
Bayer
Enrollment
56
Primary Endpoint
Evaluation of inflammatory responses
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The primary objective of this tudy was to evaluate the potential of photoallergy of of sun care products Sun Protection Factor (SPF) 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104 application compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

The secondary objective aims for evaluation of the safety of SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104 combined with ultraviolet (UV) A/B irradiation by monitoring adverse events (AEs) throughout the study.

Registry
clinicaltrials.gov
Start Date
March 23, 2015
End Date
May 8, 2015
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Bayer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Men or women, aged 18 to 65 with good general health
  • Fitzpatrick skin type I IV
  • Females (of childbearing potential) on acceptable measure of contraception
  • Willing to follow study rules, which include: no sun exposure (for example, no swimming, sunbathing, or tanning beds), avoidance of activities that would cause excessive sweating, no use of lotions, creams, or oils on the back area
  • Willing to not change the current brand of personal care products such as soaps, body washes, laundry detergent, body sprays, body spritzes, etc. while participating in the study

Exclusion Criteria

  • Not provided

Arms & Interventions

SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104

All test products compared to that of a negative control \[0.9% NaCl\] were tested simultaneously on each subject.

Intervention: SPF 50 Y65 110 (BAY987519)

SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104

All test products compared to that of a negative control \[0.9% NaCl\] were tested simultaneously on each subject.

Intervention: SPF 50 Y51 002 (BAY987519)

SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104

All test products compared to that of a negative control \[0.9% NaCl\] were tested simultaneously on each subject.

Intervention: SPF 15 V27 104 (BAY987519)

SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104

All test products compared to that of a negative control \[0.9% NaCl\] were tested simultaneously on each subject.

Intervention: Sodium chloride [NaCl]

Outcomes

Primary Outcomes

Evaluation of inflammatory responses

Time Frame: up to 3 weeks

Inflammatory responses (Based on scores): 0 = No visible reaction + = Slight, confluent, or patchy erythema 1 = Mild erythema (pink) 2 = Moderate erythema (definite redness) 3 = Strong erythema (very intense redness)

Evaluation of superficial effects

Time Frame: up to 3 weeks

Superficial effects: g = Glazing y = Peeling c = Scab, dried film of serous exudate of vesicular or bulla reaction d = Hyperpigmentation (reddish brown discoloration of test site) h = Hypopigmentation (loss of visible pigmentation at test site) f = Fissuring grooves in the superficial layers of the skin

Secondary Outcomes

  • Adverse event collection as a measure of safety and tolerability(up to 3 weeks)

Similar Trials